5Petersen P,Boysen G,GodtfredsenJ,et al.PlaCeboOcon2 trolled.randomisedtrialofwarfafin and aspir in for preven 2 fionofihrom boemboliccomp lications i nchronicatrialfi brilla 2 tion.The Copen hagen.AFASAK study.Lancet,1989,8631(1):175.
6HartRG,PearceLA,McBrideR,etal.Factorsas sociated with ischemics troked uringaspir in the rapyina trial fibrilla 2 tion:analysis of 2012 partici pants in the SPAF-clini 2 caltrials.The Stroke Preven tion in Atria l Fibrill ation(SPAF) Inves figators.Stroke,1999,30(6):1223.
6Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA, 1999, 281(19): 1830-1835.
7Feinberg WM, Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1.2 and international normalized ratin in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke, 1997, 28(6): 1101-1106.
8Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med,1996, 124(11): 970-979.
9Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fiorillation. The Copenhagen AFASAK study. Lancet, 1989, 1(8631): 175-179.
10Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012participants in the SPAF Ⅰ-Ⅲ clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke, 1999, 30(6): 1223-1229.
